Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.71% | -12.18% | -49.45% | -77.93% | -126.79% |
| Total Depreciation and Amortization | 333.33% | 1,066.67% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.85% | -1.27% | -12.63% | -19.86% | -21.47% |
| Change in Net Operating Assets | 548.21% | -72.51% | -58.23% | -139.77% | -123.35% |
| Cash from Operations | -7.10% | -31.26% | -97.46% | -164.32% | -250.71% |
| Capital Expenditure | 57.95% | 67.61% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -26,734.07% | -99.25% | 201.35% | -- | -- |
| Cash from Investing | -76,680.85% | -134.92% | 200.41% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 111.92% | -99.10% | 243.18% | 243.18% | 242.87% |
| Repurchase of Common Stock | 41.67% | 56.31% | 21.52% | -38.18% | -9.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -312.50% | -- | -274.36% | -691.30% | -- |
| Cash from Financing | 110.08% | -100.38% | 235.06% | 238.83% | 240.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -274.36% | -1,495.51% | 122.42% | -32.06% | -321.08% |